Stanford Medicine magazine explores the molecules behind human biology and how understanding them fuels medical discoveries and innovations.
Researchers at Stanford Medicine are working to develop antivirals to stop the current pandemic and prevent ones.
Stanford researchers are developing a faster way to match each ulcerative colitis patient with the treatment that will work best for them.
Researchers discuss the need for ethics and its integration into research projects that harness artificial intelligence.
A Stanford patient improved greatly after being the first person with sight-threatening thyroid eye disease to receive the drug teprotumumab.
Stanford researchers are investigating the use of a small molecule to treat Dravet syndrome, a devastating childhood neurologic disorder.
The common antidepressant Prozac melts away glioblastoma tumors in laboratory mice, suggesting possible treatment for the deadly cancer.
To help us understand muscle loss as we age, a Stanford Medicine research team’s engineered tissue is sent to the International Space Station.
Anthony Oro is devoted to understanding the origin of basal cell carcinomas. Now he's found how some become resistant to a common treatment.
Stanford Medicine researchers have discovered a drug that could potentially be used to stave off SARS-CoV-2, the virus that causes COVID-19.
Obadia Mfuh Kenji joined Stanford after the pandemic's first surge in May 2020, overcoming challenges to help deploy COVID-19 testing.
Stanford researchers have found a good drug target for treating Diamond-Blackfan anemia, a genetic disease that impairs red blood cell formation.
Stanford University bioengineers are developing a faster-acting formulation of insulin that can help diabetes patients better regulate their blood sugar levels.
How exactly does the antiviral drug remdesivir counter SARS-CoV-2 – the coronavirus strain responsible for COVID-19? And how well?
A Stanford microbiologist describes the invigorating, yet sobering race to develop an effective vaccine against COVID-19.
The Innovative Medicines Accelerator builds on existing programs at Stanford — but fills in gaps to help researchers turn ideas into drugs.
